Q1 2026 · 13F-HR
Frazier Life Sciences Management, L.P.holdings as filed
Filed 2026-05-15 · accession 0001892134-26-000002
The Brief · Frazier Life Sciences Management, L.P. · Q1 2026
AI · grounded in 13F
Frazier Life Sciences Management, L.P. closed its position in Avidity Biosciences Inc RNAGBP, reducing exposure by $70.9M. The fund also exited positions in Abivax SA ABVX and Rapt Therapeutics Inc RAPT, totaling $84.3M in combined sales. On the buy side, the fund established new positions in BioCryst Pharmaceuticals Inc BCRX for $38.2M and Aclaris Therapeutics Inc ACRS for $18.5M. Additionally, it increased its share count in Palvella Therapeutics Inc NE PVLA by 22.1%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 604749101 | MIRM | MIRUM PHARMACEUTICALS INC | $709.4M | 18.3% | 7,679,684 | Common | SOLE |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $542.4M | 14.0% | 16,943,774 | Common | SOLE |
| 29479A108 | ERAS | ERASCA INC | $399.2M | 10.3% | 24,675,188 | Common | SOLE |
| 10806X102 | BBIO | BRIDGEBIO PHARMA INC | $256.1M | 6.59% | 3,448,139 | Common | SOLE |
| 03969K108 | ARQT | ARCUTIS BIOTHERAPEUTICS INC | $232.6M | 5.99% | 9,874,511 | Common | SOLE |
| 55287L101 | MBX | MBX BIOSCIENCES INC | $198.6M | 5.11% | 6,652,013 | Common | SOLE |
| 71722W107 | PHAT | PHATHOM PHARMACEUTICALS INC | $138.5M | 3.56% | 12,466,489 | Common | SOLE |
| 578784100 | MAZE | MAZE THERAPEUTICS INC | $136.3M | 3.51% | 4,567,274 | Common | SOLE |
| 501147102 | KRYS | KRYSTAL BIOTECH INC | $124.3M | 3.20% | 481,307 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $118.6M | 3.05% | 9,939,547 | Common | SOLE |
| 697947109 | PVLA | PALVELLA THERAPEUTICS INC NE | $110.0M | 2.83% | 882,400 | Common | SOLE |
| 483497103 | KALV | KALVISTA PHARMACEUTICALS INC | $99.9M | 2.57% | 4,961,108 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $86.6M | 2.23% | 1,354,852 | Common | SOLE |
| 23282W605 | CYTK | CYTOKINETICS INC | $76.4M | 1.97% | 1,159,879 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $65.7M | 1.69% | 675,686 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS INC | $57.2M | 1.47% | 3,153,082 | Common | SOLE |
| 805111101 | SVRA | SAVARA INC | $53.1M | 1.37% | 9,720,852 | Common | SOLE |
| 87650L103 | TARS | TARSUS PHARMACEUTICALS INC | $51.1M | 1.32% | 728,644 | Common | SOLE |
| 929033207 | VOR | VOR BIOPHARMA INC | $45.4M | 1.17% | 2,543,939 | Common | SOLE |
| 00847X104 | AGIO | AGIOS PHARMACEUTICALS INC | $42.5M | 1.09% | 1,256,080 | Common | SOLE |
| 09058V103 | BCRX | BIOCRYST PHARMACEUTICALS INC | $38.2M | 0.98% | 4,009,240 | Common | SOLE |
| 98887Q104 | ZLAB | ZAI LAB LTD | $35.8M | 0.92% | 1,902,320 | Common | SOLE |
| 05153U107 | AURA | AURA BIOSCIENCES INC | $34.1M | 0.88% | 5,100,000 | Common | SOLE |
| 004225108 | ACAD | ACADIA PHARMACEUTICALS INC | $32.0M | 0.82% | 1,438,198 | Common | SOLE |
| 04351P101 | ASNDUSD | ASCENDIS PHARMA A/S | $30.5M | 0.78% | 133,333 | Common | SOLE |
| 52886X107 | LXEO | LEXEO THERAPEUTICS INC | $25.4M | 0.65% | 4,424,725 | Common | SOLE |
| G01767105 | ALKS | ALKERMES PLC | $24.8M | 0.64% | 700,647 | Common | SOLE |
| 00461U105 | ACRS | ACLARIS THERAPEUTICS INC | $18.5M | 0.48% | 4,925,374 | Common | SOLE |
| 61225M102 | GLUE | MONTE ROSA THERAPEUTICS INC | $16.4M | 0.42% | 1,000,000 | Common | SOLE |
| 45258D105 | IMCR | IMMUNOCORE HLDGS PLC | $14.6M | 0.38% | 484,782 | Common | SOLE |
| 56400P706 | MNKD | MANNKIND CORP | $14.5M | 0.37% | 5,900,000 | Common | SOLE |
| 92025Y103 | VALN | VALNEVA SE | $14.3M | 0.37% | 2,291,666 | Common | SOLE |
| 30052C107 | EOLS | EVOLUS INC | $10.8M | 0.28% | 2,630,665 | Common | SOLE |
| N62509117 | NAMSW | NEWAMSTERDAM PHARMA COMPANY | $10.0M | 0.26% | 500,333 | Common | SOLE |
| 019770106 | ALLO | ALLOGENE THERAPEUTICS INC | $9.3M | 0.24% | 3,796,668 | Common | SOLE |
| 05280R100 | AUTL | AUTOLUS THERAPEUTICS LTD | $6.1M | 0.16% | 4,447,910 | Common | SOLE |
| 451033708 | IBIO | IBIO INC | $3.7M | 0.10% | 1,953,467 | Common | SOLE |
| 98422T209 | XLO | XILIO THERAPEUTICS INC | $3.6M | 0.09% | 422,505 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.